Zentalis Pharmaceuticals

Developing small molecule #therapeutics targeting fundamental biological pathways of #cancers

[Zentalis Pharmaceuticals @ZentalisP]

As of August 2025, we are no longer active on X. Please follow us on LinkedIn moving forward for company updates.

[Zentalis Pharmaceuticals @ZentalisP]

Today we’re excited to share our Q1 2025 results, highlighting strong clinical momentum supporting our goal to bring new treatment options to patients with platinum-resistant ovarian cancer.

https://t.co/Xc6K2kS9Vt

[Zentalis Pharmaceuticals @ZentalisP]

We're excited to share that the first patient has been dosed in Part 2 of the DENALI study, which is evaluating azenosertib in patients with Cyclin E1+ platinum-resistant ovarian cancer (PROC).

Read more: https://t.co/zH6IcuXPaw

[Zentalis Pharmaceuticals @ZentalisP]

#AACR25 is right around the corner! The Zentalis team is excited to present four posters highlighting our azenosertib program.

Learn more: https://t.co/om8EhIi784

[Zentalis Pharmaceuticals @ZentalisP]

Today we report our full year 2024 results and operational updates, including highlighting previously announced positive clinical data for azenosertib in cyclin E1+ platinum-resistant ovarian cancer (PROC).

Read more in the full release: https://t.co/IjQHFusU9J

[Zentalis Pharmaceuticals @ZentalisP]

This past weekend we shared updated clinical data from our DENALI Part 1b trial of azenosertib in PROC at the SGO 2025 Annual Meeting on Women’s Cancer.

Read more: https://t.co/pvtPf2iDBz

View the presentations: https://t.co/BLXezhENUw
#SGO2025 #SGOMtg

[Zentalis Pharmaceuticals @ZentalisP]

Will you be at Champions Oncology Translational Oncology Symposium? If so, don't miss a talk from Zentalis Senior Scientist Dr. Joanna Guo.

View the full agenda: https://t.co/tSHsF3SO2K

[Zentalis Pharmaceuticals @ZentalisP]

REMINDER: We are hosting a virtual corporate presentation this Wednesday at 8:00AM EST!

Tune in for updated azenosertib clinical data as well as insights into our regulatory and development plans. A recording will also be available following the event.

https://t.co/59s9PHJPfx

[Zentalis Pharmaceuticals @ZentalisP]

📅 Finally, join our Jan 29 virtual event for updates on azenosertib clinical data and development strategy.

[Zentalis Pharmaceuticals @ZentalisP]

We're excited to share several updates in our latest press release.

Read Here: https://t.co/auPDk7fXe8

[Zentalis Pharmaceuticals @ZentalisP]

📚 New research published in npj Precision Oncology highlights Cyclin E1/CDK2 as a biomarker for azenosertib sensitivity.

[Zentalis Pharmaceuticals @ZentalisP]

Earlier this week we shared that the FDA has lifted the partial clinical hold on our azenosertib studies.

Read the full release here: https://t.co/HcJFfe8RMe

[Zentalis Pharmaceuticals @ZentalisP]

We’ve landed in Barcelona for #ESMO24! Stop by our poster and say hello to Associate Director Jianhui Ma, who will be sharing new preclinical data on azenosertib combined with topoisomerase I inhibitor-based ADCs.

https://t.co/cqeECDjsun

[Zentalis Pharmaceuticals @ZentalisP]

We're thrilled to announce that Dr. Huili Zhu is the recipient of the 2024 Zentalis Women Who Conquer Cancer Young Investigator Award.

Led by @ConquerCancerFd, this award helps clinical oncology fellows transition to faculty appointments.

[Zentalis Pharmaceuticals @ZentalisP]

May is #OncologyNursingMonth – thank you to all the oncology nurses out there for your tireless dedication and unwavering support for cancer patients and their families. Your work does not go unnoticed, and we greatly appreciate you.

[Zentalis Pharmaceuticals @ZentalisP]

Today marks the start of #NationalWomensHealthWeek – are you up to date on your checkups and screenings? Tests such as Pap smears and mammograms can help detect cancer earlier, increasing the likelihood of treatment success.

[Zentalis Pharmaceuticals @ZentalisP]

Today is #WorldOvarianCancerDay. This disease is often referred to as the "silent killer" because symptoms can be subtle, leading to late-stage diagnosis.

Zentalis is dedicated to changing this narrative, developing new treatments to help patients live longer, fuller lives.

[Zentalis Pharmaceuticals @ZentalisP]

This morning, we shared our first quarter financial results and recent operational progress. Read the full release here: https://t.co/Jequwab6BD

[Zentalis Pharmaceuticals @ZentalisP]

On this day, we want to express our gratitude to all the incredible women who drive innovation, inspire change, and make a positive impact in our workplace as well as in the broader life sciences. Your dedication, passion, and leadership are truly remarkable.

#IWD2024